Michael L. Mohler - Concepedia

Author

Michael L. Mohler

University of Tennessee Health Science Center ORCID

Also Known As

M Möhler, M. L. Mohler, Michael L Mohler, Michael L. Mohler, Mohler, M.L.

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

University of Tennessee Health Science Center The Ohio State University 490 BioTech (United States)

About

Michael L. Mohler is an author at University of Tennessee Health Science Center specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	359
2	Engineering	1	1	12
3	Health Sciences	1	1	17
4	Natural Sciences	1	1	27
5	Allergy	1	1	33

Michael L. Mohler

Publications

665

Citations

H-Index

Page 1

	Year	Citations
Design, Synthesis, and SAR Studies of 4-Substituted Methoxylbenzoyl-aryl-thiazoles Analogues as Potent and Orally Bioavailable Anticancer Agents Yan Lü, Chien-Ming Li, Zhao Wang, Journal of Medicinal Chemistry	2011	107
A Ligand-Based Approach To Identify Quantitative Structure−Activity Relationships for the Androgen Receptor Casey E. Bohl, Cheng Chang, Michael L. Mohler, Journal of Medicinal Chemistry	2004	73
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity Dong‐Jin Hwang, Yali He, Suriyan Ponnusamy, Journal of Medicinal Chemistry Combinatorial ChemistryAndrogen ReceptorMedicinal ChemistryUrologyNew Compounds	2018	64
Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators Casey E. Bohl, Zengru Wu, Jiyun Chen, Bioorganic & Medicinal Chemistry Letters BiochemistryFunctional SelectivityMedicineAnabolic SteroidsHormonal Receptor	2008	46
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer Yali He, Dong‐Jin Hwang, Suriyan Ponnusamy, Journal of Medicinal Chemistry	2021	38
Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates Michael L. Mohler, Vipin A. Nair, Dong‐Jin Hwang, Expert Opinion on Therapeutic Patents Androgen ReceptorGynecologyPharmacotherapyOvarian CancerMedicinal Chemistry	2005	37
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer Yali He, Dong‐Jin Hwang, Suriyan Ponnusamy, Journal of Medicinal Chemistry	2020	35
Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer Dong‐Jin Hwang, Huiping Xu, Igor M. Rakov, Bioorganic & Medicinal Chemistry Medicinal ChemistryUrologyMedicineAnabolic SteroidsHormonal Receptor	2006	34
Dissociated non-steroidal glucocorticoids: tuning out untoward effects Michael L. Mohler, Yali He, Zhongzhi Wu, Expert Opinion on Therapeutic Patents InflammationMetabolic SyndromeSynthetic Steroidal GcsAllergyNon-steroidal Gcs	2007	33
Discovery of Antiglioma Activity of Biaryl 1,2,3,4-Tetrahydroisoquinoline Derivatives and Conformationally Flexible Analogues Michael L. Mohler, Gyong-Suk Kang, Seoung‐Soo Hong, Journal of Medicinal Chemistry Chemoprevention StrategyHigh-grade GliomasHeterocycle ChemistryConformationally Flexible AnaloguesGlioma	2006	27

Page 1